EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment

Peng Zhang, Yi Wan, Jinrong Ma, Jin Gong, Ziwei Zhong, Yuxin Cui, Hongli Zhang, Yanyan Da, Junpeng Ma, Chenxi Li, Lijuan Liu, Tian Gong und 2 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03717-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Peng Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Dada…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Microenvironment, Epigenesis, Genetic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, The Natural Science Foundation of Jiangxi Province, China, The start-up fund from the First Affiliated Hospital of Nanchang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lactate dehydrogenase B (LDHB) reversibly catalyzes the conversion of pyruvate to lactate or lactate to pyruvate and expressed in various malignancies. However, the role of LDHB in modulating immune responses against hepatocellular carcinoma (HCC) remains largely unknown. Here, we found that down-regulation of lactate dehydrogenase B (LDHB) was coupled with the promoter hypermethylation and knocking down the DNA methyltransferase 3A (DNMT 3A) restored LDHB expression levels in HCC cell lines. Bioinformatics analysis of the HCC cohort from The Cancer Genome Atlas revealed a significant positive correlation between LDHB expression and immune regulatory signaling pathways and immune cell infiltrations. Moreover, immune checkpoint inhibitors (ICIs) have shown considerable promise for HCC treatment and patients with higher LDHB expression responded better to ICIs. Finally, we found that overexpression of LDHB suppressed HCC growth in immunocompetent but not in immunodeficient mice, suggesting that the host immune system was involved in the LDHB-medicated tumor suppression. Our findings indicate that DNMT3A-mediated epigenetic silencing of LDHB may contribute to HCC progression through remodeling the tumor immune microenvironment, and LDHB may become a potential prognostic biomarker and therapeutic target for HCC immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor MicroenvironmentEpigenesis, GeneticL-Lactate DehydrogenaseDNA Methyltransferase 3AHumansAnimalsMiceGene Expression Regulation, NeoplasticDNA MethylationIsoenzymesCell Line, TumorGene SilencingPrognosis

Stichwörter der Autor:innen

DNA methylationDNMT3AHepatocellular carcinoma (HCC)LDHBTumor microenvironment

Substanzen

L-Lactate DehydrogenaseDNA Methyltransferase 3ADNMT3A protein, humanIsoenzymeslactate dehydrogenase 1

Autor:innen und Institutionen

  • Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Dadao, Nanchang, 330209, China.
  • Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwai Zhengjie, Nanchang, 330006, China.
  • Jiangxi Provincial Center for Advanced Diagnostic Technology and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 1519 Dongyue Dadao, Nanchang, 330209, China.
  • Jiangxi Medical Academy of Nutrition and Health Management, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwai Zhengjie, Nanchang, 330006, China.
  • Cancer Center, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, China.
  • Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, China.

Förderung

  • The National Natural Science Foundation of China
  • The Natural Science Foundation of Jiangxi Province, China
  • The start-up fund from the First Affiliated Hospital of Nanchang University

Zitieren

APA

Zhang, P., Wan, Y., Ma, J., Gong, J., Zhong, Z., Cui, Y., Zhang, H., Da, Y., Ma, J., Li, C., Liu, L., Gong, T., Tan, Y., & Zhang, C. (2024). Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03717-2

Vancouver

Zhang P, Wan Y, Ma J, Gong J, Zhong Z, Cui Y, et al. Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03717-2

BibTeX
@article{Zhang2024,
  author = {Zhang, Peng and Wan, Yi and Ma, Jinrong and Gong, Jin and Zhong, Ziwei and Cui, Yuxin and Zhang, Hongli and Da, Yanyan and Ma, Junpeng and Li, Chenxi and Liu, Lijuan and Gong, Tian and Tan, Youwen and Zhang, Chengsheng},
  title = {Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03717-2}
}
Kostenlos starten →